Literature DB >> 15983210

Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass.

Jennifer Roccisana1, Vasumathi Reddy, Rupangi C Vasavada, Jose A Gonzalez-Pertusa, Mark A Magnuson, Adolfo Garcia-Ocaña.   

Abstract

Overexpression of hepatocyte growth factor (HGF) in the beta-cell of transgenic mice enhances beta-cell proliferation, survival, and function. In the current studies, we have used conditional ablation of the c-met gene to uncover the physiological role of HGF in beta-cell growth and function. Mice in which c-met is inactivated in the beta-cell (MetCKO mice) display normal body weight, blood glucose, and plasma insulin compared with control littermates. In contrast, MetCKO mice displayed significantly diminished glucose tolerance and reduced plasma insulin after a glucose challenge in vivo. This impaired glucose tolerance in MetCKO mice was not caused by insulin resistance because sensitivity to exogenous insulin was similar in both groups. Importantly, in vitro glucose-stimulated insulin secretion in MetCKO islets was decreased by approximately 50% at high glucose concentrations compared with control islets. Furthermore, whereas insulin and glucokinase expression in MetCKO islets were normal, GLUT-2 expression was decreased by approximately 50%. These changes in beta-cell function in MetCKO mice were not accompanied by changes in total beta-cell mass, islet morphology, islet cell composition, and beta-cell proliferation. Interestingly, however, MetCKO mice display an increased number of small islets, mainly single and doublet beta-cells. We conclude that HGF/c-met signaling in the beta-cell is not essential for beta-cell growth, but it is essential for normal glucose-dependent insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983210     DOI: 10.2337/diabetes.54.7.2090

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  44 in total

1.  Hepatocyte growth factor ameliorates hyperglycemia and corrects β-cell mass in IRS2-deficient mice.

Authors:  Juan C Alvarez-Perez; Taylor C Rosa; Gabriella P Casinelli; Shelley R Valle; Jayalakshmi Lakshmipathi; Carolina Rosselot; Francisco Rausell-Palamos; Rupangi C Vasavada; Adolfo García-Ocaña
Journal:  Mol Endocrinol       Date:  2014-12

2.  Novel proapoptotic effect of hepatocyte growth factor: synergy with palmitate to cause pancreatic {beta}-cell apoptosis.

Authors:  José A González-Pertusa; John Dubé; Shelley R Valle; Taylor C Rosa; Karen K Takane; José M Mellado-Gil; Germán Perdomo; Rupangi C Vasavada; Adolfo García-Ocaña
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

Review 3.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

Review 4.  Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion.

Authors:  Mira M Sachdeva; Doris A Stoffers
Journal:  Mol Endocrinol       Date:  2009-02-05

Review 5.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

6.  Biological roles of hepatocyte growth factor-Met signaling from genetically modified animals.

Authors:  Takashi Kato
Journal:  Biomed Rep       Date:  2017-10-18

7.  Promise and challenges on the horizon of MET-targeted cancer therapeutics.

Authors:  Yu-Wen Zhang
Journal:  World J Biol Chem       Date:  2015-05-26

Review 8.  Emerging Roles of Vascular Endothelium in Metabolic Homeostasis.

Authors:  Xinchun Pi; Liang Xie; Cam Patterson
Journal:  Circ Res       Date:  2018-08-03       Impact factor: 17.367

9.  Lack of beta-catenin in early life induces abnormal glucose homeostasis in mice.

Authors:  S Dabernat; P Secrest; E Peuchant; F Moreau-Gaudry; P Dubus; N Sarvetnick
Journal:  Diabetologia       Date:  2009-06-10       Impact factor: 10.122

10.  Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death.

Authors:  Dong Wei; Jie Li; Miaoda Shen; Wei Jia; Nuoqi Chen; Tao Chen; Dongming Su; Haoming Tian; Shusen Zheng; Yifan Dai; Allan Zhao
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.